Compare Revvity Inc (RVTY) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Royal Bank of Canada — how do they compare? Revvity Inc trades at $116.25 (market cap $12.91B), while Royal Bank of Canada trades at $213.01 (market cap $292.32B). The key difference: Royal Bank of Canada is far larger — about 22.6× Revvity Inc's market cap, and Royal Bank of Canada pays the higher dividend (2.37%). Which is the better fit depends on your goals.
| RVTY | RY | |
|---|---|---|
Market Cap | $12.91B | $292.32B |
Sector | Technology | Financials |
52-Week High | $117.75 | $217.87 |
52-Week Low | $82.26 | $134.80 |
Enterprise Value | $15.23B | — |
Dividend Yield | 0.24% | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Royal Bank of Canada (RY) trades at $212.67, up 0.89% today, with a bullish technical signal and recent quarterly earnings beats. The stock shows strong fundamentals with 2025 revenue of $66.53B and net income of $20.36B, yielding a 31.85% net margin. Analyst consensus is mixed with 43% buy ratings, while recent news highlights insider selling and dividend declarations.
RY presents a solid investment case with robust profitability and dividend appeal, but risks include high valuation multiples and mixed institutional sentiment. Upside is supported by earnings momentum, though macroeconomic and competitive pressures warrant caution for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
